Date: 2017-01-05
Type of
information: Initiation of development program
phase:
Announcement: initiation of development program
Company: RondinX (Israel)
Product: microbiome computational platform
Action
mechanism:
Disease:
Therapeutic
area: Inflammatory diseases - Gastrointestinal diseases - Metabolic diseases
Country:
Trial
details:
Latest
news:
- • On January 5, 2017, RondinX, an emerging pioneer in intelligent microbiome drug development, unveiled a novel approach to discovering how changes in the human microbiome affect health and disease.
- Founded in 2016, the company has built a microbiome
technology platform set to unlock the potential of microbiome therapeutics. Its technology, including its PTR (Peak-to-Trough) family of algorithms, exclusively licensed from YEDA (the commercial arm of the Weizmann Institute of Science), is a proprietary, cloud-based, computational pipeline, integrating raw metagenomics, other omics and patient metadata to derive both static and dynamic
strain level insights into the bacterial ecosystem. This platform adds a new dimension to the microbiome drug development process by profiling and predicting microbial growth dynamics from single metagenomic samples.
The current generation of microbiome drug discovery platforms provide merely a snapshot of the microbiota, a breakdown of the types of organisms present and their
relative frequency in a patient’s gut. This static snapshot falls short of providing the industry with a comprehensive tool for understanding the relationship between human microbiomes and disease. Furthermore, RondinX platform has proven to be
hypersensitive to various types of microbiome perturbations and is able to prioritize and streamline potential therapeutic strategies. By using microbiome analytics including growth dynamics, the link between certain members of the microbiome community and specific diseases states has been
demonstrated. The results, which were published in SCIENCE in 2015, indicated that type II diabetes and inflammatory bowel disease are uniquely associated with
changes in bacterial growth rates. These links could not be observed in the static microbiome population studies based on relative frequency, and therefore, unveiled unique targets for drug discovery that would have remained invisible to other
approaches.
Is
general: Yes
